(24/7 MARKET NEWS) – Pharvaris (Nasdaq: PHVS) announced, this morning, positive top-line data for RAPIDe-1, a global Phase 2 study of PHVS416 for the on-demand treatment of HAE attacks, and CHAPTER-1, a global proof-of-concept Phase 2 study of PHVS416, anticipated 2H2023.
The clinical-stage company also reported cash and cash equivalents of EUR198 million as of September 30, 2022.
Pharvaris is trading at $3.47, 86 cents higher (+32.95%), on nearly 300 thousand premarket shares traded.
Its 52-week range is $1.77 to 27.50. Its next inflection points are $3.49, $3.65 and $4.01.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
